Abstract:Owing to the intensification of chemotherapy, the complete remission (CR), overall survival (OS), disease free survival (DFS) and event free survival (EFS) rates in childhood AML have been significantly improved during the past two decades in western countries. However, reports on the long-term outcome of this disease in Chinese children remain to be very limited. Objectives The aims of this study were to investigate the outcome and prognostic factors in Chinese childhood AML treated in our hospital during the past 7 years and to provide the basis for further improvement of outcome in children with AML. Methods From April 1998 to August 2005, 96 children (51 boys and 45 girls, aged 1.5 ~ 16.1 yrs with a median age of 9) with de novo AML diagnosed in our hospital based on MICM criteria were enrolled into this study. In total, 57 patients with non-APL AML were treated with the induction therapy of daunorubicin (maximum total cumulative dose 360 mg/M2) + Ara-C (DA) or homoharringtonine + Ara-C (HA), post-remission therapy with high-dose (1~2 g/M2 q12h for 6 doses) Ara-C containing regimens for three-month courses, and low-dose therapy with daunorubicin, homoharringtonine, etoposide (maximum total cumulative dose 1800 mg/M2) and Ara-C for three-month courses, followed by maintenance therapy for a total of 2~2.5 yrs. The 39 patients with APL were treated with all-trans retinoic acid (ATRA) and drugs above. Results Out of 96 patients, 86 children (89.6%) achieved CR. The estimated OS rates at three, five and seven years were (67.2±5.5)%, (58.1±6.4)% and (49.6±8.0)%, respectively, while the EFS rates were (52.3±5.8)%, (47.6±6.2)% and (47.6±6.2)%, and the DFS rates were (55.9±6.0)%, (50.7±6.4)% and (50.7±6.4)%, respectively. Univariant analysis showed that the variables predicted higher CR rates included the WBC counts (93.2% for patients < 100 × 109/L vs 50.0% for those ≥ 100 × 109/L, P = 0.004) at diagnosis, and the blasts (100% for patients without blasts vs 85.2% for those with blasts, P = 0.023) in the peripheral blood. The variables predicted longer survival duration included WBC counts ((49.1±6.5)% of 5yr EFS for patients < 100 × 109/L vs (33.3±18.0)% for those ≥ 100 × 109/L, P = 0.022) at diagnosis, FAB subtypes ((55.9±9.7)% for M3 vs (40.4±7.7)% for non-M3, P =0.048), course numbers [(76.0±12.2)% of 5-yr ESF for 1 course vs (31.1±9.0)% for more than 2 courses, P = 0.026) for achieving CR, CD38+ ((57.9± 7.3)% for CD38+ vs (16.7%± 10.8)% for CD38−, P = 0.005), CD14− ((49.9± 7.3)% for CD14− vs (21.5%± 14.2)% for CD14+, P = 0.001), CD34− ((54.7± 9.7)% for CD34− vs (32.6%± 8.8)% for CD34+, P = 0.038) and HLA-DR- ((57.7± 17.7)% for HLA-DR- vs (39.9%± 7.4)% for HLA-DR+, P = 0.024). 17 patients lost follow-up. The total cumulative relapse rate was 31.6% (25/79) with all BM relapse. The total treatment related modality rate was 5.3%. No secondary malignancy case was identified. Conclusions DA-based induction and high dose Ara-C-based post-remission treatment are effective to improve the CR rate and long-term survival in Chinese children with AML. The results are comparable to those reported in western countries. Initial WBC counts, early response to chemotherapy, FAB subtypes and some immunological markers are proved to be the significant prognostic factors for childhood AML under our current protocol.

Achieving Optimal Response at 12 Months is Associated with a Better Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia: a Prospective, Longitudinal, Single Center Study.

Early BCR-ABL1 Decline in Imatinib-Treated Patients with Chronic Myeloid Leukemia: Results from a Multicenter Study of the Chinese CML Alliance

Health-related Quality of Life in Children with Chronic Myeloid Leukemia in the Chronic Phase

Real‐world Data of Chronic Myelomonocytic Leukemia: A Chinese Single‐center Retrospective Study

Outcome Prediction by the Transcript Level of BCR-ABL at 3 Months in Patients with Chronic Myeloid Leukemia Treated with Imatinib--a Single Institution Historical Experience.

Concordant Optimal Molecular and Cytogenetic Responses at Both 3 and 6 Months Predict a Higher Probability of MR4.5 Achievement in Patients with Chronic Myeloid Leukemia Treated with Imatinib.

Molecular Responses of Late Chronic Phase Chronic Myeloid Leukemia Patients after Achieving Complete Cytogenetic Responses with Imatinib Treatment: a 6-Year Follow-Up

Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib

Comparison of Response over 6 Years Between Patients with Chronic Myeloid Leukemia Who Received Imatinib As Initial Therapy and Those Who Received Imatinib As Secondary Therapy.

Predictive value of early molecular response for deep molecular response in chronic phase of chronic myeloid leukemia

Investigation of Long-Term Follow-Up Results of 135 Patients with Chronic Myeloid Leukemia Receiving Imatinib

Adolescents Experienced More Treatment Failure Than Children with Chronic Myeloid Leukemia Receiving Imatinib As Frontline Therapy: a Retrospective Multicenter Study

[Comparison of Nilotinib Vs Imatinib As Frontline Therapy in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase].

Which Method Better Evaluates the Molecular Response in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients with Imatinib Treatment, BCR-ABL(IS) or Log Reduction from the Baseline Level?

[Evaluation of Impact of Baseline ABL Kinase Domain Point Mutations on Response to Nilotinib in Imatinib-Resistant Or-Intolerant Patients with Chronic Myeloid Leukemia].

Long-Term Follow-Up of Treatment Outcome and Prognosis in 96 Chinese Children with Acute Myeloid Leukemia: A Single Center Experience.

Seven-year response to imatinib as initial treatment versus re-treatment in Chinese patients with chronic myelogenous leukemia in the chronic phase

Health-related quality of life in children with childhood acute myeloid leukemia in China: A five-year prospective study

Health‐related quality of life among pediatric patients with acute lymphoblastic leukemia: An exploratory cross‐sectional study

Optimized therapeutic strategy for patients with refractory or relapsed acute myeloid leukemia: long‐term clinical outcomes and health‐related quality of life assessment

Nilotinib efficacy, safety, adherence and impact on quality of life in newly diagnosed patients with chronic myeloid leukaemia in chronic phase: a prospective observational study in daily clinical practice